Proteomic and Genomic Profiling of Pancreatic Cancer

Guest Editor:

Dr. Aftab Alam
Department of Immunology, Roswell Park Comprehensive Cancer Center, Elm & Carlton Sts. CGP/BLSC-L5307, Buffalo, NY 14263, USA

Deadline for manuscript submissions:
15 September 2024

Message from the Guest Editor

Dear Colleagues,

Pancreatic cancer is one of the deadliest forms of cancer, with a 5-year survival rate of 10%. The most common treatment for pancreatic cancer is surgery and chemotherapy; however, to date, both strategies have had limited success. To combat pancreatic cancer, in recent years, a significant amount of attention has been paid to immunotherapy and personalized medicine. PD1 therapy and presently available CART therapies are failing to treat pancreatic cancer, and there is a pressing need to collect more clinical biomarkers for the development of new therapeutic targets for personalized medicine. In the age of high-throughput techniques, genomics and proteomics in particular have had a significant impact on identifying mutations in oncogenes such as KRAS and other relevant new biomarkers for chemotherapy and immunotherapy. Using the current understanding of immunotherapy, genomics and proteomics analysis of pancreatic cancer patient samples will lead to the discovery of new targets that will help in the development of novel therapeutics.

Dr. Aftab Alam
Guest Editor

mdpi.com/si/168723

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us